

Christine Leong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7197275/publications.pdf>

Version: 2024-02-01

34
papers

518
citations

687220

13
h-index

677027

22
g-index

34
all docs

34
docs citations

34
times ranked

829
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of alcohol use disorder on alcohol-related cancers, diabetes, ischemic heart disease and death: a population-based, matched cohort study. <i>Addiction</i> , 2022, 117, 368-381.	1.7	10
2	Trends of Utilization of Antiseizure Medications Among Pregnant Women in Manitoba, Canada: A 20-Year Population-Based Study. <i>Frontiers in Pharmacology</i> , 2022, 13, 871136.	1.6	4
3	Psychotropic Medication Use Before and During COVID-19: A Population-Wide Study. <i>Frontiers in Pharmacology</i> , 2022, 13, 886652.	1.6	15
4	Trends of COVID-19 incidence in Manitoba and public health measures: March 2020 to February 2022. <i>BMC Research Notes</i> , 2022, 15, 162.	0.6	11
5	Insights into patient characteristics and documentation of the use of sedative-hypnotic/anxiolytics in primary care: a retrospective chart review study. , 2022, 23, 111.		0
6	Long-Acting Injectable Antipsychotics in a Prescription Claims Data Source: A Validation Study. <i>Drugs - Real World Outcomes</i> , 2022, , .	0.7	1
7	Outpatient oral anticancer agent utilization and costs in Manitoba from 2003 to 2016: a population-based study. <i>Canadian Journal of Public Health</i> , 2021, 112, 530-540.	1.1	4
8	Physical assessment in pharmacy practice: Perspectives from pharmacists, nonpharmacist health care providers and the public. <i>Canadian Pharmacists Journal</i> , 2021, 154, 193-204.	0.4	0
9	The 5-year pre- and post-hospitalization treated prevalence of mental disorders and psychotropic medication use in critically ill patients: a Canadian population-based study. <i>Intensive Care Medicine</i> , 2021, 47, 1450-1461.	3.9	15
10	Use of pharmacotherapy for alcohol use disorder in Manitoba, Canada: A whole-population cohort study. <i>PLoS ONE</i> , 2021, 16, e0257025.	1.1	6
11	Patient values and preferences on polypharmacy and deprescribing: a scoping review. <i>International Journal of Clinical Pharmacy</i> , 2021, 43, 1461-1499.	1.0	3
12	Risk of long-term benzodiazepine and Z-drug use following the first prescription among community-dwelling adults with anxiety/mood and sleep disorders: a retrospective cohort study. <i>BMJ Open</i> , 2021, 11, e046916.	0.8	5
13	Psychotropic medication use before and after suicidal presentations to the emergency department: A longitudinal analysis. <i>General Hospital Psychiatry</i> , 2020, 63, 68-75.	1.2	9
14	Health service use among Manitobans with alcohol use disorder: a population-based matched cohort study. <i>CMAJ Open</i> , 2020, 8, E762-E771.	1.1	2
15	Persistence of use of prescribed cannabinoid medicines in Manitoba, Canada: a population-based cohort study. <i>Addiction</i> , 2019, 114, 1791-1799.	1.7	14
16	Prescription medication use during pregnancies that resulted in births and abortions (2001-2013): A retrospective population-based study in a Canadian population. <i>PLoS ONE</i> , 2019, 14, e0211319.	1.1	20
17	Translating Benzodiazepine Utilization Data into Meaningful Population Exposure: Integration of Two Metrics for Improved Reporting. <i>Clinical Drug Investigation</i> , 2018, 38, 565-572.	1.1	15
18	Pharmaceutical cannabinoid use in Manitoba, 2004/05 to 2014/15: a population-based cross-sectional study. <i>CMAJ Open</i> , 2018, 6, E637-E642.	1.1	1

#	ARTICLE	IF	CITATIONS
19	New antidepressant use in older adults: a Canadian population-based study (1997-2013). <i>Aging and Mental Health</i> , 2017, 21, 720-729.	1.5	3
20	Cerebrovascular, Cardiovascular, and Mortality Events in New Users of Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine Reuptake Inhibitors. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 332-340.	0.7	16
21	Psychotropic Drug Use before, during, and after Pregnancy: A Population-Based Study in a Canadian Cohort (2001-2013). <i>Canadian Journal of Psychiatry</i> , 2017, 62, 543-550.	0.9	30
22	Pharmacist medication reviews: Some hopeful comments about a negative finding. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2017, 57, 298.	0.7	0
23	Pharmacist-led interventions for the management of medication misuse and abuse: A systematic review. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2017, 57, 297-298.	0.7	0
24	Benzodiazepines and Z-Drugs: An Updated Review of Major Adverse Outcomes Reported on in Epidemiologic Research. <i>Drugs in R and D</i> , 2017, 17, 493-507.	1.1	181
25	Opioid use during pregnancy: a population-based cohort study. <i>CMAJ Open</i> , 2017, 5, E517-E523.	1.1	17
26	Validity of the days supply field in pharmacy administrative claims data for the identification of blister packaging of medications. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1540-1545.	0.9	1
27	Community Pharmacists' Perspectives on Dispensing Medications With the Potential for Misuse, Diversion, and Intentional Overdose: Results of a Province-Wide Survey of Community Pharmacists in Canada. <i>Substance Use and Misuse</i> , 2016, 51, 1724-1730.	0.7	14
28	Antiepileptic use for epilepsy and nonepilepsy disorders. <i>Neurology</i> , 2016, 86, 939-946.	1.5	29
29	Treating Recurrent Postmenopausal Vasomotor Symptoms in a Patient with a Positive Family History for Breast Cancer. <i>The Consultant Pharmacist</i> , 2015, 30, 38-44.	0.4	1
30	Student perspectives of an online module for teaching physical assessment skills for dentistry, dental hygiene, and pharmacy students. <i>Journal of Interprofessional Care</i> , 2015, 29, 383-385.	0.8	13
31	Antidepressants for Depression in Patients with Dementia: A Review of the Literature. <i>The Consultant Pharmacist</i> , 2014, 29, 254-263.	0.4	45
32	A Physical Assessment Skills Module on Vital Signs. <i>American Journal of Pharmaceutical Education</i> , 2014, 78, 137.	0.7	11
33	Treatment Strategies for Recurrent <i>Clostridium difficile</i> Infection. <i>Canadian Journal of Hospital Pharmacy</i> , 2013, 66, 361-8.	0.1	21
34	Emerging Therapies for the Management of Multiple Sclerosis. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S2213.	0.4	1